Abstract
The role of osteopontin as a biomarker in endometrial cancer has not been conclusively established. We evaluated the expression and potential of osteopontin as a biomarker for endometrial cancer. Real-time polymerase chain reaction and immunohistochemistry revealed osteopontin overexpression in endometrial cancer. The plasma osteopontin level in endometrial cancer was significantly higher than in healthy controls (P < 0.001). In FIGO stage I endometrial cancer, osteopontin correctly identified 18 of 29 cases (62.1%) that were not detected by CA125. By Cox multivariate analysis, osteopontin positivity was an independent prognostic factor for disease-free survival (hazard ratio = 3.18, P= 0.035).
| Original language | English |
|---|---|
| Pages (from-to) | 313-323 |
| Number of pages | 11 |
| Journal | Cancer Investigation |
| Volume | 27 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2009 Mar 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
}
Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. / Cho, Han Byoul; Kang, Eun Suk; Kim, YoungTae; Kim, Jae-Hoon.
In: Cancer Investigation, Vol. 27, No. 3, 01.03.2009, p. 313-323.Research output: Contribution to journal › Article
TY - JOUR
T1 - Diagnostic and prognostic impact of osteopontin expression in endometrial cancer
AU - Cho, Han Byoul
AU - Kang, Eun Suk
AU - Kim, YoungTae
AU - Kim, Jae-Hoon
PY - 2009/3/1
Y1 - 2009/3/1
N2 - The role of osteopontin as a biomarker in endometrial cancer has not been conclusively established. We evaluated the expression and potential of osteopontin as a biomarker for endometrial cancer. Real-time polymerase chain reaction and immunohistochemistry revealed osteopontin overexpression in endometrial cancer. The plasma osteopontin level in endometrial cancer was significantly higher than in healthy controls (P < 0.001). In FIGO stage I endometrial cancer, osteopontin correctly identified 18 of 29 cases (62.1%) that were not detected by CA125. By Cox multivariate analysis, osteopontin positivity was an independent prognostic factor for disease-free survival (hazard ratio = 3.18, P= 0.035).
AB - The role of osteopontin as a biomarker in endometrial cancer has not been conclusively established. We evaluated the expression and potential of osteopontin as a biomarker for endometrial cancer. Real-time polymerase chain reaction and immunohistochemistry revealed osteopontin overexpression in endometrial cancer. The plasma osteopontin level in endometrial cancer was significantly higher than in healthy controls (P < 0.001). In FIGO stage I endometrial cancer, osteopontin correctly identified 18 of 29 cases (62.1%) that were not detected by CA125. By Cox multivariate analysis, osteopontin positivity was an independent prognostic factor for disease-free survival (hazard ratio = 3.18, P= 0.035).
UR - http://www.scopus.com/inward/record.url?scp=63349090034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63349090034&partnerID=8YFLogxK
U2 - 10.1080/07357900802375738
DO - 10.1080/07357900802375738
M3 - Article
VL - 27
SP - 313
EP - 323
JO - Cancer Investigation
JF - Cancer Investigation
SN - 0735-7907
IS - 3
ER -